Sponsor or institution

Clinical trials and research at Swiss Cancer Institute

• 12Clinical trials
• 2Countries

Newest trials

All recruiting trials (12)

• Understanding why BRAF V600E colorectal cancer stops responding to targeted therapy

  This study tests why metastatic colorectal cancer with a BRAF V600E mutation stops responding to encorafenib and cetuximab, by collecting tissue, blood, and stool samples over time.

  Recruiting at 13 sites Swiss Cancer Institute · Aarau and 12 other locations · NCT07617610

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

• MELCHRONO: Chrono-immunotherapy timing for advanced melanoma

  This study tests whether giving immune checkpoint inhibitors at specific times of day improves outcomes for adults with advanced melanoma.

  Recruiting at 9 sites Phase 2 Swiss Cancer Institute · Fribourg, Canton of Fribourg and 8 other locations · NCT07574047

• Terbinafine for prostate cancer with rising PSA after local treatment

  This phase II test gives oral terbinafine to men with biochemical recurrence after definitive local therapy and no visible metastases to see if it slows PSA rise and delays starting hormone therapy.

  Recruiting at 11 sites Phase 2 Swiss Cancer Institute · Baden and 10 other locations · NCT07365423

• Gemcitabine plus Ivonescimab for advanced NSCLC that progressed after immunotherapy

  This trial tests whether combining gemcitabine with ivonescimab can help people with advanced NSCLC whose cancer has grown after prior chemo-immunotherapy.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Baden and 7 other locations · NCT07158489

• Magnesium supplementation added to standard chemo-immunotherapy in advanced NSCLC

  This trial tests whether giving magnesium along with standard chemo-immunotherapy helps people with advanced non-small cell lung cancer.

  Recruiting at 9 sites Phase 2/3 Swiss Cancer Institute · Aarau and 8 other locations · NCT07149649

• Reduced-dose carboplatin doublet plus cemiplimab versus cemiplimab alone for older, frail metastatic NSCLC with PD-L1 under 50%

  This will test whether adding lower-dose carboplatin-based doublet chemotherapy to cemiplimab helps people aged 70 and older who are frail and have metastatic NSCLC with PD-L1 under 50% do better than cemiplimab alone.

  Recruiting at 18 sites Phase 2 Swiss Cancer Institute · Fribourg, Villars-sur-Glâne and 17 other locations · NCT07020065

• Total pre-surgery chemotherapy plus regional hyperthermia for high-risk limb and trunk soft tissue sarcoma (TNT-HYPE)

  This trial will test whether giving three cycles of chemotherapy with regional hyperthermia before radiation and surgery is feasible and tolerable for people with high-risk soft tissue sarcoma of the arms, legs, or trunk.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 7 other locations · NCT06835049

• Doxycycline to target breast cancer stem cells in early ER+/HER2- disease

  We will test whether giving the antibiotic doxycycline together with standard pre-surgery chemotherapy helps people with early ER+/HER2- breast cancer by targeting cancer stem cells and improving treatment response.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Sankt Gallen, Canton of St. Gallen and 7 other locations · NCT06452394

• Using darolutamide for advanced prostate cancer treatment

  This study is testing if darolutamide can help men with advanced prostate cancer who have already been treated feel better and live longer without their cancer getting worse.

  Recruiting at 12 sites Phase 2 Swiss Cancer Institute · Aarau and 12 other locations · NCT06401980

• Treatment for early triple-negative breast cancer using INT230-6 and immuno-chemotherapy

  This study is testing a new treatment called INT230-6, combined with chemotherapy, to see if it can help people with early-stage triple-negative breast cancer have better outcomes before surgery.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Lyon and 9 other locations · NCT06358573

• Comparing systemic therapy alone versus with local treatment for advanced lung cancer

  This study is testing if adding local treatments like surgery or radiation to standard therapy can help people with advanced lung cancer live longer and feel better after their initial treatment.

  Recruiting at 7 sites Swiss Cancer Institute · Aarau and 6 other locations · NCT06114108

Quick answers

How many clinical trials run by Swiss Cancer Institute are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in Switzerland (12 trials), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 9, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →